| scholarly article | Q13442814 |
| P2093 | author name string | T C Wu | |
| Chenguang Wang | |||
| Chien-Fu Hung | |||
| Lawrence S Lamb | |||
| Michael G Conner | |||
| Ronald D Alvarez | |||
| Warner K Huh | |||
| Bradford E Jackson | |||
| Sejong Bae | |||
| Jean Boyer | |||
| Cornelia L Trimble | |||
| Emily A Adams | |||
| Elizabeth Sauter | |||
| Mihaela Paradis | |||
| Shirley Hester | |||
| P2860 | cites work | Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI) | Q30444086 |
| Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels | Q30534669 | ||
| Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments | Q33713435 | ||
| Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia | Q33783092 | ||
| A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. | Q33834057 | ||
| Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions | Q33862762 | ||
| Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination | Q33864400 | ||
| Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3 | Q34033800 | ||
| Immune surveillance in the skin: mechanisms and clinical consequences | Q34308222 | ||
| Control of HPV infection and related cancer through vaccination | Q34368905 | ||
| Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses | Q35049821 | ||
| Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. | Q35113700 | ||
| ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial | Q35644707 | ||
| Induction of antitumor immunity in vivo following delivery of a novel HPV-16 DNA vaccine encoding an E6/E7 fusion antigen | Q35771332 | ||
| Cellular immunity induced by a novel HPV18 DNA vaccine encoding an E6/E7 fusion consensus protein in mice and rhesus macaques | Q35771342 | ||
| The immunobiology of the TLR9 subfamily | Q35810913 | ||
| Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. | Q36097429 | ||
| Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen | Q36167792 | ||
| A skin-selective homing mechanism for human immune surveillance T cells | Q36399490 | ||
| Immortalization and altered differentiation of human keratinocytes in vitro by the E6 and E7 open reading frames of human papillomavirus type 18. | Q36800223 | ||
| Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b tri | Q36954152 | ||
| HPV vaccines to prevent cervical cancer and genital warts: an update | Q38194254 | ||
| Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. | Q39982103 | ||
| Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 | ||
| Reproducibility of HPV 16 and HPV 18 viral load quantitation using TaqMan real-time PCR assays | Q44570595 | ||
| Clinical safety and efficacy of a powdered Hepatitis B nucleic acid vaccine delivered to the epidermis by a commercial prototype device. | Q51419221 | ||
| The vast majority of CLA+ T cells are resident in normal skin. | Q51984006 | ||
| Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. | Q52584352 | ||
| SIV DNA vaccine co-administered with IL-12 expression plasmid enhances CD8 SIV cellular immune responses in cynomolgus macaques | Q57081543 | ||
| Integration of the HPV16 genome does not invariably result in high levels of viral oncogene transcripts | Q81165889 | ||
| Loop electrosurgical excision procedure and the risk for preterm delivery | Q86700036 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | cervical intraepithelial neoplasia | Q196788 |
| P304 | page(s) | 245-252 | |
| P577 | publication date | 2015-11-23 | |
| P1433 | published in | Gynecologic Oncology | Q5625182 |
| P1476 | title | A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). | |
| P478 | volume | 140 |
| Q64244575 | Anti-Cancer Vaccine for HPV-Associated Neoplasms: Focus on a Therapeutic HPV Vaccine Based on a Novel Tumor Antigen Delivery Method Using Endogenously Engineered Exosomes |
| Q40051093 | Attitudes towards Human Papilloma Virus Vaccination in the Latin American Andean Region. |
| Q37579334 | Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis |
| Q38792909 | Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation |
| Q92213753 | Current status of therapeutic HPV vaccines |
| Q37626311 | DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection |
| Q59350795 | DNA Vaccines-How Far From Clinical Use? |
| Q56967486 | Emerging human papillomavirus vaccines |
| Q55086081 | Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model. |
| Q37198835 | Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination |
| Q92576163 | Human CD4+ T Cells Specific for Merkel Cell Polyomavirus Localize to Merkel Cell Carcinomas and Target a Required Oncogenic Domain |
| Q64060870 | Immune deviation and cervical carcinogenesis |
| Q92043562 | Immune responses to a HSV-2 polynucleotide immunotherapy COR-1 in HSV-2 positive subjects: A randomized double blinded phase I/IIa trial |
| Q38697123 | Immunologic responses to a novel DNA vaccine targeting human papillomavirus-11 E6E7. |
| Q26744094 | Immunotherapy for human papillomavirus-associated disease and cervical cancer: review of clinical and translational research |
| Q92030460 | Importance of the immune system in head and neck cancer |
| Q45324266 | In vivo electroporation enhances vaccine-mediated therapeutic control of human papilloma virus-associated tumors by the activation of multifunctional and effector memory CD8+ T cells |
| Q37107984 | Incisal margin condition after LEEP for cervical intraepithelial neoplasia patients and prognosis |
| Q35812239 | Intravaginal HPV DNA vaccination with electroporation induces local CD8+ T-cell immune responses and antitumor effects against cervicovaginal tumors |
| Q37473299 | Moving forward with human papillomavirus immunotherapies |
| Q36616505 | Optimization of heterologous DNA-prime, protein boost regimens and site of vaccination to enhance therapeutic immunity against human papillomavirus-associated disease |
| Q28069272 | Perspectives for therapeutic HPV vaccine development |
| Q92061657 | Perspectives in HPV Secondary Screening and Personalized Therapy Basing on Our Understanding of HPV-Related Carcinogenesis Pathways |
| Q33907700 | Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection |
| Q50052586 | Targeted immunotherapy of high-grade cervical intra-epithelial neoplasia: Expectations from clinical trials |
| Q54217605 | Targeting Head and Neck Cancer by Vaccination. |
| Q39033576 | The current state of therapeutic and T cell-based vaccines against human papillomaviruses |
| Q92905364 | The efficacy and safety of Tipapkinogen Sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up |
| Q50115667 | Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases. |
| Q47255618 | Therapeutic vaccines for high-risk HPV-associated diseases. |
| Q34438411 | Toll-like receptor agonist imiquimod facilitates antigen-specific CD8+ T-cell accumulation in the genital tract leading to tumor control through IFNγ |
| Q56893452 | Trial watch: DNA-based vaccines for oncological indications |
| Q61797559 | Turning the corner on therapeutic cancer vaccines |
Search more.